Headed to Philadelphia for the American Transplant Congress (ATC)? Stop by Booth 218 to learn more about our work in primary #hyperoxaluria type 1 (PH1) and join us on Sunday, June 2 at 2:30 p.m. ET for our PH1 symposium. Learn more: https://bit.ly/3R71XLz #ATC2024Philly #RNAiTherapeutics #RNAi #siRNA
Alnylam Pharmaceuticals
Biotechnology Research
Cambridge, Massachusetts 192,266 followers
Alnylam is the leading RNAi therapeutics company. We're a fast-growing biopharma with a deep pipeline and global reach.
About us
To those who say “impossible, impractical, unrealistic,” we say: “CHALLENGE ACCEPTED.” Alnylam is the world's leading RNAi therapeutics company and the first and only company to bring RNAi-based medicines to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) and ocular diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNAi, and a bold vision that this discovery could be used to silence disease-causing genes upstream of today’s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Alnylam is turning scientific possibility into reality - in 2018, the FDA and EMA approved of our first product, ONPATTRO (patisiran) which is also the first-ever approved RNAi therapeutic. We now have four additional medicines on the market. Our robust pipeline of investigational medicines includes multiple programs in late-stage and early-stage clinical development. We are a global and diverse company of 2,000+ people. We pride ourselves on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That's why we've been named a Science Magazine Top Employer 5 years in a row ('19-'23), a Boston Globe Top Place to Work 9x in a row ('15-'23) and Fast Company's #1 Best Workplace for Innovators ('22). We are based in Cambridge, U.S., with offices throughout Europe, Asia, and South America. See our community guidelines: https://bit.ly/2FcRhJy.
- Website
-
http://www.alnylam.com
External link for Alnylam Pharmaceuticals
- Industry
- Biotechnology Research
- Company size
- 1,001-5,000 employees
- Headquarters
- Cambridge, Massachusetts
- Type
- Public Company
- Founded
- 2002
- Specialties
- Biotech, Pharmaceuticals, Biopharma, Drug Development, Rare Diseases, and RNAi
Locations
Employees at Alnylam Pharmaceuticals
Updates
-
Led by our SHADES: InspirASIAN Employee Resource Network, we’re proud to Celebrate #AAPIHeritageMonth. All year long, InspirASIAN, as part of our SHADES multicultural network, works to foster connections, professional development and mentoring while celebrating the diverse cultures represented by the Asian and Asian American Pacific Islander community. #AAPI #AAPIMonth
-
-
Did you know that RNA interference (RNAi) is a naturally occurring cellular process that’s already at work inside your body? It has two primary functions – to regulate gene expression (i.e., making new proteins) and viral defense. Alnylam scientists have harnessed this natural process to treat specific diseases. Are you #ScienceCurious to know more? Read this Nature Portfolio article (sponsored content) to learn how RNAi therapeutics, and Alnylam, are disrupting disease. https://bit.ly/49YgpNq #RNAi #RNAinterference #siRNA #GeneSilencing #RNAiAmScienceCurious
-
We recently shared new subgroup results from the KARDIA-1 Phase 2 study of zilebesiran, an investigational #RNAi therapeutic for the treatment of #hypertension. Learn more: https://bit.ly/3QJU66w #siRNA
-
-
In recognition of Global Porphyria Day, our employees around the world showed their support for the acute hepatic #porphyria (AHP) community by going #PurpleForPorphyria. Earlier this week, we also had the opportunity to sit down with Heather, who is living with AHP, along with patient advocacy leaders Nicole Castellano of the American Porphyria Foundation and Kristen Wheeden of the United Porphyrias Association, and porphyria expert Dr. Rebecca Karp. Together, they shared their #MyPorphyria stories and discussed the important role of advocacy, barriers to diagnosing AHP and how we can help raise awareness of this #RareDisease. #GPD2024
-
With warmer months and family gatherings ahead, summer is the perfect time to discuss health with your loved ones. Hear from Renee and her father, Julio, who uncovered a health mystery that goes back generations at a family reunion. Learn more about #hATTR #amyloidosis here: https://bit.ly/3QPohJd #hATTRoadTrip
-
We shared new 54-month results from our Phase 2 open-label extension study to evaluate the long-term administration of our #RNAi therapeutic for the treatment of primary #hyperoxaluria type 1 (PH1) at the 61st European Renal Association Congress (#ERA24). Learn more about the findings: https://bit.ly/3VbFQpJ
-
-
Across our offices, we’re recognizing #MentalHealth awareness month with programming and activities. In our Cambridge HQ and other offices yesterday, employees had the opportunity to build their own mental health kits and our CEO Dr. Yvonne Greenstreet got in on the action! #MentalHealthAwearenessMonth #CorporateWellness
-
-
Can we geek out for a sec?! Among the many breakthroughs that our founders made when they started collaborating at the Massachusetts Institute of Technology (MIT) in 2000 was the ability to synthesize small interfering RNAs (siRNAs) and transfect them into cells. This pioneering work in #RNAinterference kicked off an era of intense development of #RNAiTherapeutics led by Alnylam, which they founded in 2002. That spirit of discovery and commitment to R&D leadership in RNAi drives us to this day and with it, the #RNAiRevolution. Read all about Alnylam's, and RNAi's, journey from interesting science to transformative new class of medicines in a new open access article from MIT News: https://bit.ly/3QNfcRd #RNAi #siRNA #MITnews #biotech #DrugDiscovery #RNAiRevolution #AlnylamScienceSpotlight
-
-
Alnylam Pharmaceuticals reposted this
It was inspiring to celebrate our remarkable CEO, Dr. Yvonne Greenstreet, HBA’s 2024 Woman of the Year, along with our outstanding Rising Stars, Lauren Sheik and Agnes Qerimi. I am especially proud of this well-deserved recognition of Lauren, an integral member of our HR team. It is an honor to work alongside such dedicated and passionate women who are making a transformative impact both at Alnylam Pharmaceuticals and in the #healthcare industry. Congratulations to these extraordinary women! #womeninleadership #HBA #AlnylamProud
A huge thank you to the Healthcare Businesswomen’s Association for an incredibly inspiring event on Friday to recognize the contributions of women in our industry who are making an extraordinary impact. And congratulations to all of this year’s HBA honorees including Alnylam Pharmaceuticals’s own Rising Stars, Lauren Sheik and Agnes Qerimi. The enormous promise we hold in health care to develop medicines that create hope and transform the lives of millions will require the kind of transformational leadership that HBA celebrates and enables. I am proud to serve as HBA’s 2024 Woman of the Year and look forward to supporting the critical work of this amazing community so deeply committed to advancing the impact of women in our field and in society. #HBAWOTY2024
-
Similar pages
Browse jobs
Stock
ALNY
NASDAQ
20 minutes delay
$148.43
-1.6 (-1.067%)
- Open
- 150
- Low
- 147.615
- High
- 151.49
Data from Refinitiv
See more info on